ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

NavnABBVON

RangeringNo.3140

Markedsverdi$0.00

Fullt utvannet markedsverdi$0.00

Markedsandel%

Handelsvolum/markedsgrense (24 timer)407,993.09%

Opplagsforsyning220.54886481

Maksimal forsyning0

Total forsyning220.54886481

Opplagsforsyning%

Utstedelsesdato--

Prisen for aktivaen da den først ble utstedt--

All-time high235.09684688380833,2026-02-17

Laveste pris207.47261007076094,2026-02-04

Offentlig blokkjedeETH

IntroduksjonAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Sektor

Sosiale medier

• Offisiell nettside
• Blokker Explorer

etfindex:mc_etfindex_sourceAnsvarsfraskrivelse: Dataene leveres av cmc og bør ikke betraktes som investeringsråd.